Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. demonstrates a positive outlook due to the encouraging clinical results from its BX211 treatment for diabetic foot osteomyelitis (DFO), which showed significant improvements across several clinical parameters including infection resolution and reductions in C-Reactive Protein levels. Additionally, the positive feedback from the FDA regarding the advancement of the BX011 multi-phage cocktail into a Phase 2a study positions BiomX favorably for potential market expansion and improved patient outcomes in cystic fibrosis. The company’s strategy to explore additional indications and broader market applications, alongside potential regulatory advancements, suggests significant upside potential for future revenues.

Bears say

BiomX Inc faces a negative outlook primarily due to the mixed results from its clinical trials, where key endpoints narrowly missed statistical significance, leading to unfavorable investor sentiment. The company could struggle to secure adequate funding to support its drug development efforts, and challenges such as dilutive capital raises further exacerbate financial risks. Additionally, the potential for failed or inconclusive clinical outcomes may hinder its chances of achieving commercial success, contributing to the pessimistic view on its stock.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.